Research
Beyond Discovery: Nexyra's Fast Track to Commercialization
Drug discovery shouldn’t crawl — it should accelerate with purpose.
At Nexyra, we redefine early-stage R&D with a new paradigm: interdisciplinary intelligence, AI-guided design, and molecular precision, all seamlessly integrated from target identification to IND-enabling studies.
We don’t just screen compounds. We orchestrate data, craft molecules, and co-create innovation with our partners — turning scientific hypotheses into clinically actionable candidates faster than ever.
Let’s co-engineer your path to first-in-human with speed, rigor and scientific audacity.
01
Target ID & Validation
Decode complex disease biology using AI-driven interactomics, CRISPR screens, and omics-based systems biology.
02
Hit Identification Services
From high-throughput screening to fragment-based discovery, we pair chemical intuition with machine learning to identify hits in record time..
03
Structural Biology
Visualize molecular architecture at atomic resolution.
04
Molecular Design & Medicinal Chemistry
Design with intent. From de novo AI-generated scaffolds to lead series optimization, we shape molecules that matter..
05
Biomarker Strategy
Precision starts with detection. We develop companion diagnostics and molecular markers that illuminate therapeutic response..
06
Sample Management
Scalable, compliant, and traceable biorepository infrastructure. Because every sample is data waiting to be activated.
Necesitamos su consentimiento para cargar las traducciones
Utilizamos un servicio de terceros para traducir el contenido del sitio web que puede recopilar datos sobre su actividad. Por favor revise los detalles en la política de privacidad y acepte el servicio para ver las traducciones.